Plain-English translation of NCT04634994 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers at Brigham and Women's Hospital want to understand how multiple sclerosis damages the brain in different ways. This study uses a special imaging scan called PET to measure something called synaptic density—essentially, how well brain cells are connected—in people with progressive MS, relapsing MS, and healthy people without MS.
Progressive forms of MS can be harder to treat and predict than relapsing forms. By measuring brain cell connections in different MS types, scientists hope to better understand why some people's MS gets worse over time, which could eventually lead to better treatments.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic up to four times. At your first visit, you'll answer health questionnaires, review the study details, and sign a consent form. Then you'll have a PET scan (a type of brain imaging) and possibly an MRI scan. Women of childbearing age will have a quick pregnancy test before imaging. The whole process takes a few weeks to complete.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Brigham and Women's Hospital
Collaborators
Massachusetts General Hospital
Enrollment target
~30 participants
Started
May 2025
Primary completion
December 2026
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tarun Singhal, MD
Brigham and Women's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.